AngioDynamics, Inc. First Quarter of Fiscal 2027 Earnings Conference Call - ANGIODYNAMICS INC

Financial Performance:

• Total revenue increased 6.9% year-over-year to $80.9 million, driven by a 13.2% growth in the MedTech segment to $39.9 million (now 49% of total revenue vs. 47% prior year).
• Gross margin expanded to 59.4%, a 410 basis point increase, driven by favorable pricing, mix shift toward higher-margin MedTech products, and $1.2 million in tariff refunds; adjusted gross margin (excluding refunds) was 57.8%.
• GAAP net loss narrowed to $7.1 million ($0.17 loss per share) from $10.9 million ($0.26 loss per share) prior year; adjusted net loss improved to $1.8 million ($0.04 loss per share) from $4.2 million ($0.10 loss per share).
• Operating expenses were $55.3 million (68.4% of sales), with R&D at $8.0 million (9.9% of sales) and SG&A at $42.5 million (52.5% of sales).
• Cash flow from operations used $15.3 million, consistent with historical Q1 seasonality; the company maintains a $34 million cash balance and a debt-free balance sheet.
• MedDevice segment revenue grew 1.4% to $41 million, providing consistent cash flow to fund MedTech investments.

Guidance and Future Outlook:

• Full-year fiscal 2027 net sales guidance remains $336 million to $341 million, representing 5% to 6.5% growth over fiscal 2026.
• Segment-specific guidance expects MedTech sales to grow 12% to 15% and MedDevice sales to remain roughly flat.
• Full-year gross margin guidance is maintained at 54% to 55%, with the first half expected to outperform the second half due to structural cost accounting and rising input costs.
• Adjusted EBITDA guidance is $13 million to $16 million; adjusted loss per share is guided to $0.23 to $0.24.
• Management expects positive cash flow from operations for the full fiscal year 2027 despite seasonal Q1 usage.

Business Segments and Product Lines:

• Ariane (Atherectomy): Generated $18.9 million (+14.7% YoY), marking 21 consecutive quarters of double-digit growth; taking share in both hospital and office-based laboratory (OBL) settings with ongoing international adoption.
• Mechanical Thrombectomy: Combined AngioVac and AlphaVac revenue was $12 million (+6.7% YoY); AlphaVac surged 37.4% to $4.5 million, while AngioVac declined 5.9% but grew sequentially 9.1%.
• NanoKnife: Revenue grew 29% to $8.3 million; probes up 24.1% and capital sales up 53.5% to record procedure volumes driven by prostate cancer applications and MAC coverage decisions.
• New Product & Indications: Received FDA approval for the RELIEF study evaluating NanoKnife for benign prostatic hyperplasia (BPH), targeting a ~$1.9 billion market.
• Clinical Trials: Advancing enrollment in the Ambition BT case study for below-knee atherectomy and continuing IDE trials for AlphaVac in right-sided infective endocarditis.

Market and Competitive Landscape:

• Competition in mechanical thrombectomy remains intense, but AngioDynamics cites its "most versatile product" and commercial execution as key drivers for taking share from competitors like AlphaVac.
• Disruptions at competitor platforms are being monitored, with management confident in winning on clinical value propositions regardless of external market volatility.
• NanoKnife adoption is expanding beyond academic centers to community urology practices and regional hospitals, particularly in the U.S. prostate market.
• The strategic mix shift is accelerating, with MedTech projected to comprise a majority of revenue by the end of fiscal 2027.

Risks and Challenges:

• Reimbursement variability remains a key driver for NanoKnife utilization; management is working to secure consistent nationwide coverage beyond the current MAC decisions.
• Tariff impacts remain dynamic, though management expects the net impact to be broadly similar to fiscal 2026, with potential for further refunds.
• Seasonality is a factor, with Q1 typically the highest cash usage quarter and Q3 structurally soft due to holiday closures in certain markets.
• Manufacturing transitions and global inflation partially offset gross margin gains, requiring ongoing cost mitigation strategies.

Management Commentary and Tone:

• CEO Jim Clemmer announced his succession by Eric Honroth (effective November 2nd), expressing full confidence in the new leader's 20+ years of medical device experience and growth track record.
• Management tone is highly confident, describing the results as the outcome of a "deliberate" and "intentional" 5-6 year transformation strategy.
• The narrative emphasizes a "patients first" philosophy, linking clinical outcomes and physician confidence directly to commercial success.
• Clemmer expressed pride in the team's ability to build a robust portfolio that competes and wins in large markets.

Analyst Questions and Answers:

• NanoKnife Ramp: Management emphasized that disposable sales, not capital placements, are the primary bellwether for growth; utilization is variable but trending positively following strong Q4 and Q1 placements.
• Thrombectomy Growth: Commercial enhancements and new headcount contributions are already driving growth, with AlphaVac serving as the primary engine over the niche AngioVac line.
• Costa Rica: Cost savings from the Costa Rica manufacturing site are fully integrated into the base, contributing to the strong underlying gross margin trajectory.
• BPH Opportunity: The RELIEF study aims to build a business case; current R&D budget (targeting ~10% of sales) is sufficient to support this expansion without requiring a strategic step-up in spending.
• Orion Market Dynamics: Management noted distinct economic differences between hospital and OBL customers but affirmed a balanced go-to-market approach, with hospitals currently driving significant share gains.
• Cash Flow Cadence: Q1 is historically the peak cash usage quarter; Q4 is typically the strongest cash generation quarter, with full-year positive cash flow expected.

Other Key Points:

• Macro-level strategy involves a "three legs to a stool" MedTech platform approach, expanding atherectomy into coronary markets and thrombectomy into new indications like PE and right-sided endocarditis.
• AlphaVac is currently benefiting from a "tougher comp" environment but is expected to return to more normal growth as the year progresses.
• The company received a CPT-1 code and Palmetto MAC decision for NanoKnife, significantly aiding reimbursement momentum in the prostate sector.